Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04269876 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation
A NA study, sponsored by Supplement Formulators.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT04269876: Clinical Trial NA study, sponsored by Supplement Formulators.
NCT04269876 is a NA study that was terminated before completion, run by Supplement Formulators. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04269876, a NA study, was terminated before completion, sponsored by Supplement Formulators.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of a Marine Lipid Oil Concentrate formulation on inflammatory biomarkers and overall well-being in male and female subjects who are overweight to mildly obese, but otherwise generally healthy.
Primary Outcome
Mean or median change in high sensitivity C-reactive protein (hs-CRP) from baseline to Day 60
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Dietary Supplement
- DIETARY_SUPPLEMENT Marine Lipid Oil Concentrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-10-31 |
| Est. Completion | 2021-09-30 |
| Phase | NA |
Why NCT04269876 stopped before completion
NCT04269876 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04269876 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04269876 about?
NCT04269876 is a clinical study titled "A Study to Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation". To assess the efficacy and safety of a Marine Lipid Oil Concentrate formulation on inflammatory biomarkers and overall well-being in male and female subjects who are overweight to mildly obese, but otherwise generally healthy.
What is the current status of trial NCT04269876?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2019-10-31. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT04269876?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Dietary Supplement (DIETARY_SUPPLEMENT), Marine Lipid Oil Concentrate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04269876?
This trial is sponsored by Supplement Formulators, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04269876's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI